Jonathan Lilly, MD
Family Medicine · Dunbar, WVNPI 1073574414
Payments from drug & device makers
Across 567 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- AstraZeneca$902
- Lilly USA, LLC$843
- Merck$370
- Johnson & Johnson$348
- plus $3K from 32 others
What the payments were for
- Food & beverage$8,743100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 168 | $1,997 |
| AbbVie | 65 | $1,055 |
| AstraZeneca | 46 | $902 |
| Lilly USA, LLC | 50 | $843 |
| Merck | 21 | $370 |
| Johnson & Johnson | 18 | $348 |
| Bayer | 25 | $333 |
| Pfizer | 20 | $313 |
| Boehringer Ingelheim | 19 | $272 |
| Dexcom, Inc. | 12 | $260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $251 |
| Sanofi-aventis U.S. LLC | 17 | $233 |
| GSK | 12 | $189 |
| Novartis | 9 | $157 |
| Shield Therapeutics Inc | 3 | $135 |
| E.r. Squibb & Sons, L.L.C. | 7 | $114 |
| Kowa Pharmaceuticals America, Inc. | 8 | $110 |
| Amgen(2 entities) | 7 | $104 |
| Astellas Pharma US Inc | 6 | $98 |
| Exact Sciences | 6 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| Lundbeck LLC | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 4 | $51 |
| Sunovion Pharmaceuticals Inc. | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $46 |
| Abbott | 3 | $45 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Concordia Pharmaceuticals Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| UCB, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,743 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $213,926 |
| JardianceEmpagliflozin | 143 | $188,880 |
| EliquisApixaban | 172 | $180,309 |
| RybelsusSemaglutide | 99 | $177,646 |
| MounjaroTirzepatide | 122 | $144,987 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $90,563 |
| FarxigaDapagliflozin Propanediol | 92 | $83,691 |
| XareltoRivaroxaban | 70 | $75,759 |
| TrulicityDulaglutide | 34 | $66,431 |
| JanuviaSitagliptin Phosphate | 51 | $66,216 |
| XifaxanRifaximin | 45 | $65,769 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $63,424 |
| EntrestoSacubitril/Valsartan | 28 | $51,254 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $40,418 |
| CreonLipase/Protease/Amylase | 12 | $39,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $1,997 | $412,892263 claims |
| Lilly USA, LLCMounjaro, Trulicity | $843 | $211,419156 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $272 | $207,297162 claims |
| PfizerEliquis | $313 | $180,309172 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $902 | $102,472120 claims |
| Johnson & JohnsonXarelto | $348 | $75,75970 claims |
| AbbVieCreon, Linzess, Synthroid | $1,055 | $73,886148 claims |
| MerckJanuvia | $370 | $66,21651 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $251 | $65,76945 claims |
| NovartisEntresto | $157 | $51,25428 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $233 | $40,41834 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $24,30424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Dunbar
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.